Antibody Name: 3α4D10 (VH SGIIC | VL kIII)
References: Tempest, P.R., White, P., Williamson, E.D., Titball, R.W., Kelly D.C., Kemp, G.J.L., Gray, P.M.D., Forster, S.J., Carr, F.J. and Harris, W.J. "Efficient generation of a reshaped human mAb specific for the alpha-toxin of Clostridium perfringens" Prot.Engng. (1994) 7:1501-1507.
Donor Antibody: mouse
Acceptor Antibody: Human IgG1 | k
Antigen: α toxin of Clostridium perfringens (Zn-metallo phospholipase C)
Epitope ARGFAK
Laboratory: Scotgen Biopharmaceuticals, UK; Porton Down, UK; University of Aberdeen, UK
Design: Fixed FR approach. Used computer model of mouse V regions.
Frameworks: Modified versions of NEWM (T107, T108) and REI (L4, K39, F71, V104, E105, K107)
CDRs: All 6 VH and VL, Kabat Definition.
Backmutations: VH S27F AR93-94NA
VL none (although see modification in FRs above)
Binding: Improved binding for versions HuVHNA and HuVHNIKNA although the former was chosen for clinical trials, assessed by relative and equilibrium binding assays. Binding to synthetic peptides showed that the specificity had been altered.
Expression: Non-secreting rat myeloma YB2/0
Comment: Scotgen use fixed frameworks (NEWM|REI) and routinely alter residues 28-30:H, 48-49:H and 91-94:H. They also individually test other positions (eg 71 in both heavy and light chains).
Clinical Indication: Gas gangrene

explanation of symbols and abbreviations

José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.